Innovent's tafolecimab meets primary endpoint as first-line monotherapy

Overview

Updated Yesterday

Innovent Biologics' tafolecimab cut LDL cholesterol by roughly 65% in a Phase 3 trial of patients who took no other lipid-lowering drug. The CREDIT-5 result is the first late-stage evidence that a Chinese-made PCSK9 antibody works as a stand-alone first-line treatment for high cholesterol.

Statins remain the default first-line therapy in China, and some patients cannot tolerate them or do not reach target on them. A PCSK9 antibody that works alone, dosed every two or four weeks, would give those patients an option that does not require a statin backbone. Innovent plans to ask China's drug regulator to add that use to the label.

Why it matters

If approved for first-line use, tafolecimab gives Chinese patients who cannot tolerate statins a domestic alternative to imported PCSK9 drugs.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

65.19%

LDL-C reduction at 12 weeks, 150 mg every two weeks

Versus a 6.61% drop on placebo; difference significant at p<0.0001.

64.01%

LDL-C reduction at 12 weeks, 450 mg every four weeks

Versus a 4.31% drop on placebo; difference significant at p<0.0001.

198

Participants randomized in CREDIT-5

131 received tafolecimab and 67 received placebo.

~50%

Reduction in lipoprotein(a)

A separate cardiovascular risk marker lowered alongside LDL cholesterol.

1 million+

Patients treated since launch

Innovent's figure for patients who have received SINTBILO in China.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Yida Tang

Professor, Peking University Third Hospital; lead principal investigator of CREDIT-5

Leading the CREDIT-5 study

Organizations Involved

Innovent Biologics

Biopharmaceutical company (HKEX: 01801)

Developer and marketer of tafolecimab

Suzhou-based drugmaker listed on the Hong Kong Stock Exchange that developed and sells tafolecimab in China.

National Medical Products Administration (NMPA)

Regulatory Agency

Will review Innovent's planned new-indication application

China's national drug regulator, which approves labels and indications for medicines sold in the country.

Peking University Third Hospital

Teaching hospital

Lead site for the CREDIT-5 trial

Beijing teaching hospital whose cardiology team led the CREDIT-5 study.

Timeline

November 2022 November 2026

5 events Latest: Today

Tap a bar to jump to that date

November 2026
Innovent signals a first-line filing with China's regulator
Today Regulatory

The company said it plans to submit a new-indication application to the NMPA in the near future.
Today
CREDIT-5 monotherapy trial meets its primary endpoint
Clinical trial

Tafolecimab alone cut LDL-C by 64% to 65% at 12 weeks versus placebo, with no serious adverse events.
Yesterday
January 2025
Tafolecimab joins China's national reimbursement list
Reimbursement

National insurance coverage took effect, lowering the out-of-pocket cost for patients.
January 1st, 2025
August 2023
Tafolecimab reaches the Chinese market
Approval

SINTBILO launched in China for adults with primary hypercholesterolemia and mixed dyslipidemia.
August 18th, 2023
November 2022
CREDIT-1 shows tafolecimab lowers LDL-C on top of statins
Clinical trial

In 618 Chinese patients already on lipid-lowering therapy, the 450 mg every-four-weeks dose cut LDL-C by 65% versus placebo at 48 weeks.
November 7th, 2022

Scenarios

NMPA adds first-line monotherapy to the tafolecimab label

Likely Resolves by End of 2027

Discussed by: Innovent's own filing announcement; the company has said it will submit a new-indication application

Innovent files the CREDIT-5 data, and the NMPA updates the label to allow use without a statin in non-familial hypercholesterolemia. That opens a patient group statins have served poorly and lets Innovent market tafolecimab before statin therapy rather than after it.

Regulators keep tafolecimab as an add-on therapy

Possible Resolves by End of 2027

Discussed by: No public signal yet; the open question is whether the NMPA accepts a single 12-week trial as enough for a first-line label

The NMPA declines the new indication or asks for longer-term data, leaving tafolecimab approved only alongside statins. Innovent would keep selling into the add-on market but could not market the drug as a stand-alone first-line option.

Chinese lipid guidelines name PCSK9 monotherapy a first-line option

Possible Resolves by End of 2027

Discussed by: Chinese cardiology guideline panels and expert consensus groups; the trial investigators argue the case

Even before or alongside a label change, a major Chinese lipid guideline lists PCSK9 inhibitor monotherapy as an option for statin-intolerant patients. Guideline language would shape prescribing behavior and insurance negotiation beyond the formal label.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2015

First PCSK9 inhibitors approved in the United States (2015)

The U.S. Food and Drug Administration cleared the first two PCSK9 antibodies, Sanofi and Regeneron's alirocumab and Amgen's evolocumab. Both were approved mainly for patients who could not tolerate statins or who needed more LDL lowering on top of them.

Then

The drugs launched at high prices and insurers pushed back, requiring prior authorization and step therapy through statins.

Now

The class settled into a niche for statin-intolerant and high-risk patients, with use growing as prices and coverage changed.

Why this matters now

Tafolecimab is trying to move the same class from add-on to first-line, a step the first Western PCSK9 drugs did not take at launch.

2017

FOURIER trial ties PCSK9 inhibition to fewer heart events (2017)

Amgen's evolocumab became the first PCSK9 inhibitor to show in a large outcomes trial that intensive LDL lowering reduced cardiovascular events, not just cholesterol numbers.

Then

The result strengthened the case that very low LDL is safe and beneficial, and it supported broader payer coverage.

Now

Outcomes data became the standard payers and guidelines expect before a PCSK9 drug is used widely.

Why this matters now

CREDIT-5 measures cholesterol reduction, not heart attacks and strokes. Innovent will eventually need outcomes evidence to match what regulators and payers expect for this class.